Motus Gi Holdings Inc (MOTS)

$0.05

Market is closed - opens 7 PM, 15 Jul 2024

Performance

  • $0.05
    $0.05
    $0.05
    downward going graph

    10.0%

    Downside

    Day's Volatility :12.62%

    Upside

    2.91%

    downward going graph
  • $0.05
    $23.40
    $0.05
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :99.79%

    Upside

    99.79%

    downward going graph

Returns

PeriodMotus Gi Holdings Inc
3 Months
-71.18%
6 Months
-95.61%
1 Year
-99.46%
3 Years
-99.98%

Highlights

Market Capitalization
294.5K
Book Value
$0.59
Earnings Per Share (EPS)
-2.96
Wall Street Target Price
8.3
Profit Margin
0.0%
Operating Margin TTM
-3165.63%
Return On Assets TTM
-62.02%
Return On Equity TTM
-1069.02%
Revenue TTM
327.0K
Revenue Per Share TTM
0.11
Quarterly Revenue Growth YOY
14.299999999999999%
Gross Profit TTM
-233.0K
EBITDA
-9.1M
Diluted Eps TTM
-2.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Motus Gi Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 16500.0%

Current $0.05
Target $8.30

Company Financials

FY18Y/Y Change
Revenue
36.0K
↑ 414.29%
Net Income
-22.3M
↑ 68.61%
Net Profit Margin
-61.8K%
↑ 126746.43%
FY19Y/Y Change
Revenue
107.0K
↑ 197.22%
Net Income
-22.6M
↑ 1.51%
Net Profit Margin
-21.1K%
↑ 40709.11%
FY20Y/Y Change
Revenue
98.0K
↓ 8.41%
Net Income
-19.6M
↓ 13.26%
Net Profit Margin
-20.0K%
↑ 1116.91%
FY21Y/Y Change
Revenue
391.0K
↑ 298.98%
Net Income
-18.9M
↓ 3.51%
Net Profit Margin
-4.8K%
↑ 15162.41%
FY22Y/Y Change
Revenue
592.0K
↑ 51.41%
Net Income
-18.1M
↓ 4.34%
Net Profit Margin
-3.1K%
↑ 1780.66%
FY23Y/Y Change
Revenue
319.0K
↓ 46.11%
Net Income
-12.9M
↓ 28.88%
Net Profit Margin
-4.0K%
↓ 977.63%
Q3 FY22Q/Q Change
Revenue
278.0K
↑ 50.27%
Net Income
-5.2M
↓ 8.16%
Net Profit Margin
-1.9K%
↑ 1195.27%
Q4 FY22Q/Q Change
Revenue
109.0K
↓ 60.79%
Net Income
-3.9M
↓ 24.97%
Net Profit Margin
-3.6K%
↓ 1716.63%
Q1 FY23Q/Q Change
Revenue
56.0K
↓ 48.62%
Net Income
-4.4M
↑ 12.61%
Net Profit Margin
-7.9K%
↓ 4284.95%
Q2 FY23Q/Q Change
Revenue
113.0K
↑ 101.79%
Net Income
-3.0M
↓ 32.09%
Net Profit Margin
-2.7K%
↑ 5228.15%
Q3 FY23Q/Q Change
Revenue
86.0K
↓ 23.89%
Net Income
-2.7M
↓ 10.61%
Net Profit Margin
-3.1K%
↓ 462.91%
Q4 FY23Q/Q Change
Revenue
64.0K
↓ 25.58%
Net Income
-2.8M
↑ 4.7%
Net Profit Margin
-4.4K%
↓ 1267.69%
FY18Y/Y Change
Total Assets
23.0M
↑ 150.37%
Total Liabilities
4.4M
↑ 21.73%
FY19Y/Y Change
Total Assets
32.3M
↑ 40.53%
Total Liabilities
13.9M
↑ 213.93%
FY20Y/Y Change
Total Assets
24.1M
↓ 25.4%
Total Liabilities
12.8M
↓ 8.29%
FY21Y/Y Change
Total Assets
26.1M
↑ 8.42%
Total Liabilities
16.4M
↑ 28.64%
FY22Y/Y Change
Total Assets
17.6M
↓ 32.36%
Total Liabilities
14.7M
↓ 10.72%
FY23Y/Y Change
Total Assets
7.2M
↓ 59.07%
Total Liabilities
4.5M
↓ 69.08%
Q3 FY22Q/Q Change
Total Assets
17.4M
↓ 13.52%
Total Liabilities
16.6M
↑ 3.07%
Q4 FY22Q/Q Change
Total Assets
17.6M
↑ 1.62%
Total Liabilities
14.7M
↓ 11.65%
Q1 FY23Q/Q Change
Total Assets
12.2M
↓ 30.69%
Total Liabilities
13.3M
↓ 9.23%
Q2 FY23Q/Q Change
Total Assets
11.7M
↓ 4.01%
Total Liabilities
12.7M
↓ 4.6%
Q3 FY23Q/Q Change
Total Assets
8.5M
↓ 27.68%
Total Liabilities
11.0M
↓ 13.66%
Q4 FY23Q/Q Change
Total Assets
7.2M
↓ 14.93%
Total Liabilities
4.5M
↓ 58.65%
FY18Y/Y Change
Operating Cash Flow
-14.9M
↑ 43.61%
Investing Cash Flow
-3.5M
↑ 365.65%
Financing Cash Flow
29.5M
↑ 358.92%
FY19Y/Y Change
Operating Cash Flow
-19.9M
↑ 33.36%
Investing Cash Flow
-5.6M
↑ 60.79%
Financing Cash Flow
28.0M
↓ 5.16%
FY20Y/Y Change
Operating Cash Flow
-17.0M
↓ 14.67%
Investing Cash Flow
8.1M
↓ 244.32%
Financing Cash Flow
9.2M
↓ 67.27%
FY21Y/Y Change
Operating Cash Flow
-14.4M
↓ 15.13%
Investing Cash Flow
-470.0K
↓ 105.79%
Financing Cash Flow
16.6M
↑ 81.44%
Q3 FY22Q/Q Change
Operating Cash Flow
-3.6M
↓ 20.74%
Investing Cash Flow
-166.0K
↑ 245.83%
Financing Cash Flow
1.3M
↑ 4028.13%

Technicals Summary

Sell

Neutral

Buy

Motus Gi Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Motus Gi Holdings Inc
Motus Gi Holdings Inc
-27.95%
-95.61%
-99.46%
-99.98%
-99.99%
Stryker Corporation
Stryker Corporation
-1.06%
7.98%
13.26%
29.73%
65.15%
Boston Scientific Corp.
Boston Scientific Corp.
0.95%
28.95%
47.17%
80.42%
83.02%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.79%
22.98%
-2.26%
-14.76%
43.0%
Abbott Laboratories
Abbott Laboratories
0.74%
-8.39%
-3.27%
-12.16%
24.35%
Medtronic Plc
Medtronic Plc
-4.54%
-9.93%
-11.47%
-38.81%
-21.91%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Motus Gi Holdings Inc
Motus Gi Holdings Inc
NA
NA
NA
0.0
-10.69
-0.62
NA
0.59
Stryker Corporation
Stryker Corporation
38.74
38.74
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
64.8
64.8
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
40.02
40.02
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.2
32.2
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
27.92
27.92
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Motus Gi Holdings Inc
Motus Gi Holdings Inc
Buy
$1.4M
-99.99%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$129.3B
65.15%
38.74
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$113.4B
83.02%
64.8
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$56.0B
43.0%
40.02
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.3B
24.35%
32.2
13.96%
Medtronic Plc
Medtronic Plc
Buy
$98.8B
-21.91%
27.92
11.36%

Institutional Holdings

  • Armistice Capital, LLC

    7.69%
  • Virtu Financial LLC

    0.67%
  • Tower Research Capital LLC

    0.44%
  • Advisor Group Holdings, Inc.

    0.12%
  • BlackRock Inc

    0.01%

Company Information

motus gi holdings, inc. (nasdaq: mots) is a medical technology company based in the u.s., with subsidiaries in the u.s. and israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. the company is focused on the development and commercialization of the pure-vu® system, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. the pure-vu® system is a 510(k) u.s. food and drug administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. the device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. the pure-vu® system has received ce mark approval in europe.

Organization
Motus Gi Holdings Inc
Employees
15
CEO
Mr. Mark Pomeranz
Industry
Health Technology

FAQs